BackNKGen Biotech Overview

NKGen Biotech Receivables

Latest receivables for NKGN: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-26000.00 vs prior year quarter

Peer average

Loading

NKGen Biotech Receivables History

Loading

NKGen Biotech vs. peers: Receivables Comparison

Loading

NKGen Biotech Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NKGen Biotech (NKGN) FAQ

As of the most recent data (March 2025), NKGN shows a receivables of $0. That compares with $26K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NKGN's receivables is now $0 (was $26K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NKGen Biotech is outperforming or lagging.

Tracking NKGN's receivables over time shows whether NKGen Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $26K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has NKGen Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.